FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
The Food and Drug Administration (FDA) has approved pembrolizumab as well as pembrolizumab and berahyaluronidase…
Author ONA Editor
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
Virus-based therapy boosts anti-cancer immune responses to brain cancer
A team led by investigators at Mass General Brigham and Dana-Farber Cancer Institute, USA, has…
ASH publishes clinical practice guidelines on frontline and relapsed/refractory management of all in adolescents and young adults
The American Society of Hematology (ASH) released guidelines on frontline management of acute lymphoblastic leukaemia…
HPV cancer vaccine slows tumour growth, extends survival in preclinical model
Throughout the past decade, Northwestern University scientists have uncovered a striking principle of vaccine design:…
Call for action on understudied lung cancer in never-smokers
Lung cancer patients who have never smoked make up a significant and growing share of…
Overall survival benefit with elenagen plus gemcitabine in platinum-resistant ovarian cancer
Dr. Gabriel Levin, gynaecologic oncologist at the McGill University Health Centre, and Director of Oncology…
Light-based sensor detects early molecular signs of cancer in the blood
Researchers have developed a highly sensitive light-based sensor that can detect extremely low concentrations of…
Lung cancer drug offers a surprising new treatment against ovarian cancer
A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response after PARP inhibitor…
Unravelling the mystery of why some immunotherapies stop working
Cancer researchers working on immunotherapies have made a big discovery: SLAMF6, a molecule on the…
Repurposed alcoholism drug targets liver cancer by targeting fat metabolism and blood supply
Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide, often driven by abnormal…